Congressman Brett Guthrie (KY-02), Chair of the House Energy and Commerce Committee’s Subcommittee on Health, recently voiced concerns about President Biden's health care agenda affecting access to life-saving cures for Americans. In an op-ed published in The Hill, Guthrie highlighted the impact of Biden's policies on innovation and affordability in the healthcare sector.
Guthrie pointed out that President Biden's approach includes "resorting to price controls and removing incentives for innovation by taking the intellectual property of innovators." This move, according to Guthrie, goes against the goals outlined in Biden's Cancer Moonshot initiative and disregards bipartisan solutions that could benefit patients immediately.
Guthrie emphasized the importance of finding policy solutions that lower the cost of prescription drugs for Americans while ensuring access to innovative treatments for those in need. He stressed the need to steer away from actions that hinder innovation and limit access to potentially life-saving cures.
The op-ed serves as a reminder of the ongoing discussions surrounding healthcare affordability and innovation in the lead-up to the 2024 presidential election cycle. Guthrie's concerns shed light on the complexities of balancing affordability and innovation in the healthcare sector, urging for a careful consideration of the implications of policy decisions on patients and the healthcare industry.
Alerts Sign-up